Journal of Clinical Medicine Review Oral Manifestations in Melanoma Patients Treated with Target or Immunomodulatory Therapies Emi Dika 1,2,* , Martina Lambertini 2 , Bruna Gouveia 3, Martina Mussi 2 , Emanuela Marcelli 4, Elena Campione 5, Carlotta Gurioli 1,2, Barbara Melotti 1, Aurora Alessandrini 1,2 and Simone Ribero 6 1 Division of Dermatology, IRCCS—Policlinico Sant’Orsola, via Massarenti 9, 40138 Bologna, Italy;
[email protected] (C.G.);
[email protected] (B.M.);
[email protected] (A.A.) 2 Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40138 Bologna, Italy;
[email protected] (M.L.);
[email protected] (M.M.) 3 The Poche Centre, Melanoma Institute of Australia, 40 Rocklands Rd, Wollstonecraft, NSW 2065, Australia;
[email protected] 4 Laboratory of Bioengineering, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40138 Bologna, Italy;
[email protected] 5 Dermatology Unit, University of Rome Tor Vergata, 00133 Roma, Italy;
[email protected] 6 Department of Medical Sciences, Dermatologic Clinic, University of Turin, 10126 Turin, Italy;
[email protected] * Correspondence:
[email protected]; Tel.: +39-0512144849 Abstract: Background: BRAF (v-raf murine sarcoma viral oncogene homolog B1) and MEK (mitogen activated protein kinase) inhibitors, as well as immunotherapy against cytotoxic T-lymphocyte- Citation: Dika, E.; Lambertini, M.; associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1) receptor and its ligand Gouveia, B.; Mussi, M.; Marcelli, E.; (PD-L1), have shown good results in improving the disease-free survival of patients with metastatic Campione, E.; Gurioli, C.; Melotti, B.; melanoma (MM).